Nature Medicine, Published online: 16 September 2026; doi:10.1038/s41591-026-04625-x
In a prospective study involving 1,785 individuals from four countries, the PANXEON exosome-based biomarker, combined with carbohydrate antigen 19-9 levels, achieves high sensitivity for the detection of early-stage pancreatic cancer.
